References
- Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, et al. Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin Nucl Med 1996; 21: 759-67.
- Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170(6 Pt 2): S84-8; discussion S88-9.
- Abdel-Nabi H, Doerr RJ, Chan HW, Balu D, Schmelter RF, Maguire RT. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology 1990; 175: 163-71.
- Moffat FL, Jr., Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996; 14: 2295-305.
- Breitz HB, Tyler A, Bjorn MJ, Lesley T, Weiden PL. Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy. Clin Nucl Med 1997; 22: 615-20.
- Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001; 19: 316-7.
- Wagnieres GA, Star WM, Wilson BC. In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem Photobiol 1998; 68: 603-32.
- Rajwa B, Bernas T, Acker H, Dobrucki J, Robinson JP. Single- and two-photon spectral imaging of intrinsic fluorescence of transformed human hepatocytes. Microsc Res Tech 2007; 70: 869-79.
- Troy T, Jekic-McMullen D, Sambucetti L, Rice B. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging 2004; 3: 9-23.
- Inoue Y, Izawa K, Kiryu S, Tojo A, Ohtomo K. Diet and abdominal autofluorescence detected by in vivo fluorescence imaging of living mice. Mol Imaging 2008; 7: 21-7.
- Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003; 9: 123-8.
- Chang K, Jaffer F. Advances in fluorescence imaging of the cardiovascular system. J Nucl Cardiol 2008; 15: 417-28.
- Ballou B. Quantum dot surfaces for use in vivo and in vitro. Curr Top Dev Biol 2005; 70: 103-20.
- Rao J, Dragulescu-Andrasi A, Yao H. Fluorescence imaging in vivo: recent advances. Curr Opin Biotechnol 2007; 18: 17-25.
- Jin ZH, Josserand V, Razkin J, Garanger E, Boturyn D, Favrot MC, et al. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol Imaging 2006; 5: 188-97.
- Thomas TP, Patri AK, Myc A, Myaing MT, Ye JY, Norris TB, et al. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules 2004; 5: 2269-74.
- Zhang T, Stilwell JL, Gerion D, Ding L, Elboudwarej O, Cooke PA, et al. Cellular effect of high doses of silica-coated quantum dot profiled with high throughput gene expression analysis and high content cellomics measurements. Nano Lett 2006; 6: 800-8.
- Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med 2005; 11: 678-82.
- Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002; 62: 4029-33.
- Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR, Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15: 1174-81.
- Lisy MR, Goermar A, Thomas C, Pauli J, Resch-Genger U, Kaiser WA, et al. In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology 2008; 247: 779-87.
- Chen CH, Chernis GA, Hoang VQ, Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA 2003; 100: 9226-31.
- Shukla R, Thomas TP, Peters JL, Desai AM, Kukowska-Latallo J, Patri AK, et al. HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem 2006; 17: 1109-15.
- Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, et al. Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007; 67: 6882-8.
- Shukla R, Thomas TP, Peters J, Kotlyar A, Myc A, Baker Jr JR. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun (Camb) 2005; 46: 5739-41.
- Cai W, Chen X. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc 2008; 3: 89-96.
- Gunn AJ, Hama Y, Koyama Y, Kohn EC, Choyke PL, Kobayashi H. Targeted optical fluorescence imaging of human ovarian adenocarcinoma using a galactosyl serum albumin-conjugated fluorophore. Cancer Sci 2007; 98: 1727-33.
- Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004; 22: 969-76.
- Kaushal S, McElroy MK, Luiken GA, Talamini MA, Moossa AR, Hoffman RM, et al. Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg 2008; 12: 1938-50.
- Virostko J, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol 2009; 11: 204-12.
- Takeda M, Tada H, Higuchi H, Kobayashi Y, Kobayashi M, Sakurai Y, et al. In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine. Breast Cancer 2008; 15: 145-52.
- Kamaly N, Kalber T, Thanou M, Bell JD, Miller AD. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug Chem 2009; 20: 648-55.
- Yang C, Ding N, Xu Y, Qu X, Zhang J, Zhao C, et al. Folate receptor-targeted quantum dot liposomes as fluorescence probes. J Drug Target 2009; 17: 502-11.
- Ferreira CS, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol 2006; 27: 289-301.
- Perkins AC, Missailidis S. Radiolabelled aptamers for tumour imaging and therapy. Q J Nucl Med Mol Imaging 2007; 51: 292-6.
- Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chemistry & Biology 1997; 4: 809-16.
- Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, et al. Tumor targeting by an aptamer. J Nucl Med 2006; 47: 668-78.
- Pieve CD, Perkins AC, Missailidis S. Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 2009; 36: 703-10.
- Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007; 7: 3065-70.
- Razkin J, Josserand V, Boturyn D, Jin ZH, Dumy P, Favrot M, et al. Activatable fluorescent probes for tumour-targeting imaging in live mice. Chem Med Chem 2006; 1: 1069-72.
- Bremer C, Bredow S, Mahmood U, Weissleder R, Tung CH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology 2001; 221: 523-9.
- Reshetnyak YK, Andreev OA, Lehnert U, Engelman DM. Translocation of molecules into cells by pH-dependent insertion of a transmembrane helix. Proc Natl Acad Sci USA 2006; 103: 6460-5.
- Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO, et al. Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc Natl Acad Sci USA 2007; 104: 7893-8.
- Jin ZH, Razkin J, Josserand V, Boturyn D, Grichine A, Texier I, et al. In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4). Mol Imaging 2007; 6: 43-55.
- Ballou B, Ernst LA, Waggoner AS. Fluorescence imaging of tumors in vivo. Curr Med Chem 2005; 12: 795-805.
- Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 2003; 13: 195-208.
- Swanson SD, Kukowska-Latallo JF, Patri AK, Chen C, Ge S, Cao Z, et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine 2008; 3: 201-10.
- Zhu W, Okollie B, Bhujwalla ZM, Artemov D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med 2008; 59: 679-85.
- Thomas TP, Majoros IJ, Kotlyar A, Kukowska-Latallo JF, Bielinska A, Myc A, et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem 2005; 48: 3729-35.
- Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000; 65: 133-48.
- Xu R, Wang Y, Wang X, Jeong EK, Parker DL, Lu ZR. In vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent. Exp Biol Med (Maywood) 2007; 232: 1081-9.
- Hill E, Shukla R, Park SS, Baker JR, Jr. Synthetic PAMAM-RGD conjugates target and bind to odontoblast-like MDPC 23 cells and the predentin in tooth organ cultures. Bioconjug Chem 2007; 18: 1756-62.
- Boswell CA, Eck PK, Regino CA, Bernardo M, Wong KJ, Milenic DE, et al. Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm 2008; 5: 527-39.
- Majoros IJ, Williams CR, Baker JR, Jr. Current dendrimer applications in cancer diagnosis and therapy. Curr Top Med Chem 2008; 8: 1165-79.
- Baker M. Whole-animal imaging: The whole picture. Nature 2010; 463: 977-80.
- Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA 2010; 107: 4317-22.
- Yildirim M, Engin O, Oztekin O, Akdamar F, Adibelli ZH. Diagnostic evaluation and surgical management of recurrent hydatid cysts in an endemic region. Radiol Oncol 2009; 43:162-9.
- Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Azmir RS et al. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43: 180-6.